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Abstract
Migraine is a disabling common brain disorder
typically characterized by attacks of severe headache
and associated with autonomic and neurological
symptoms. Its etiology is far from resolved. This
review will focus on evidence that epigenetic
mechanisms play an important role in disease
etiology. Epigenetics comprise both DNA methylation
and post-translational modifications of the tails of
histone proteins, affecting chromatin structure and
gene expression. Besides playing a role in establishing
cellular and developmental stage-specific regulation
of gene expression, epigenetic processes are also
important for programming lasting cellular responses
to environmental signals. Epigenetic mechanisms may
explain how non-genetic endogenous and exogenous
factors such as female sex hormones, stress hormones
and inflammation trigger may modulate attack
frequency. Developing drugs that specifically target
epigenetic mechanisms may open up exciting new
avenues for the prophylactic treatment of migraine.
Keywords: DNA methylation, epigenetics, GWAS, his-
tone modifications, inflammation, migraine, stress,
valproate
Background
Migraine is a common, disabling brain disorder typically
characterized by attacks of 4 to 72 h of severe headache
and associated autonomic and neurological symptoms [1].
In 30% of patients attacks may be preceded by neurologi-
cal aura symptoms, the likely consequence of a wave of
neuronal and glial depolarization called cortical spreading
depression (CSD) Activation of the trigeminovascular sys-
tem is responsible for migraine pain. Migraine affects over
15% of the general population, with around 10% of
migraine patients suffering from weekly attacks [2]. Cur-
rent acute and prophylactic treatments are effective in less
than half of the patients [2], indicating the need for more
effective drugs. Identifying factors that predispose to
migraine attacks is therefore crucial to provide specific
molecular targets to design novel migraine drugs.
It is becoming increasingly clear that epigenetic processes
play an important role in a wide variety of multifactorial dis-
eases [3]. The question we aim to address here is: do they
also play a role in migraine? Epigenetics encompasses
changes to the DNA structure without changing the genetic
code, resulting in chromatin remodeling and consequently
affecting transcriptional potential and expression of genes.
The main epigenetic modifications or ‘marks’ are post-trans-
lational modifications of the tails of histone proteins and
DNA methylation, collectively comprising the epigenome
(Figure 1). These marks are catalyzed by enzymes including
histone deacetylases (HDACs), histone acetyltransferases
(HATs) and DNA methyltransferases (DNMTs). Epigenetic
marks can be dynamic but can also be stably inherited
through cell divisions. Therefore, epigenetic processes
enable cell and developmental stage-specific regulation of
gene expression, but also play an important role in program-
ming lasting responses to environmental cues.
This review highlights current evidence for an epige-
netic link with migraine and speculates on neurobiologi-
cal pathways that may be programmed by epigenetic
mechanisms.
Environmental factors and migraine
Although there is a clear genetic component to migraine,
environmental factors likely contribute approximately
equally to the risk of developing migraine [4]. Environ-
mental factors may directly trigger migraine attacks or
lower the attack threshold by rendering the brain more
susceptible to trigger factors. Modulators of migraine
attack frequency include female sex hormones, given that
migraine affects two to three times more females than
males, and the occurrence is influenced by the menstrual
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cycle and pregnancy, as well as by hormonal contracep-
tives [5]. Moreover, menopause, with its reduced estrogen
and progesterone production, is associated with a decline
in migraine attack frequency [6].
Animal studies have provided further evidence that
female hormones can affect mechanisms directly involved
in migraine pathophysiology. For instance, female trans-
genic migraine mice carrying a pathogenic gene mutation
that causes familial hemiplegic migraine (FHM) in humans
[7] have an increased susceptibility for CSD induction com-
pared to male transgenic migraine mice [8,9]. Ovariectomy
of these female migraine mice reduced the susceptibility for
CSD induction, which was partially abrogated by estrogen
replacement [9]. In addition, several studies in rats showed
that estrogen treatment, ovariectomy as well as the men-
strual cycle can alter the activity of the trigeminal nocicep-
tive pathway [10]. The effects of female hormones are
predominantly transmitted via nuclear receptors that adjust
epigenetic programming of their target genes [11]. For
instance, estrogen receptor b regulates expression of
glucose transporter Glut4 by maintaining a low level of
DNA methylation at its promoter, thereby enabling its acti-
vation [12]. Notably, treatment of mice with an estrogen
receptor b agonist increased g-aminobutyric acid (GABA)
synthesis [13], whereas estrogen receptor a activation
enhanced expression of astrocytic glutamate transporter
Glast (also known as Slc1a3 and Eaat1) [14], thereby chan-
ging the balance between inhibitory and excitatory neuro-
transmission. This balance seems to be affected in
migraine, resulting in increased excitatory neuronal activity,
that is, creating hyperexcitability [15]. This is supported by
the observation in a transgenic FHM1 mouse model that
excitatory, glutamatergic, cortical neuronal activity was
increased [16].
Another environmental factor that can modulate the
occurrence of migraine attacks is stress. The stress sys-
tem is highly sensitive to environmental programming
through epigenetic mechanisms. The first study that
assessed the effect of stress on the epigenome showed
that low maternal care, a model for early life stress, could
lastingly affect the behavior and stress responsiveness of
rat offspring throughout their lifespan through increased
DNA methylation at the brain-specific promoter of the
glucocorticoid receptor gene Nr4a3, the main receptor
for glucocorticoid stress hormones [17]. Other studies
have linked stress during early life as well as during
Figure 1 Proposed model in which epigenetic factors influence migraine pathophysiology. Different factors such as hormones,
inflammation and neuronal activity can result in chromatin remodeling events affecting the expression of genes and pathways involved in the
onset and progress of migraine and comorbid disorders such as depression. The hyperexcitability observed in migraine itself acts on the
epigenome, thus creating a feed-forward loop resulting in chronification of migraine.
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adulthood to a wide variety of long-lasting epigenetic
alterations at stress effector genes (for example, Bdnf, Gr
and Crh), affecting structural and functional aspects of
the brain such as stress reactivity and synaptic plasticity
[18]. In migraine, short-lasting stressful periods are
among the most frequently reported trigger factors [19].
Moreover, early life stress may lead to an increased risk
for migraine in humans [20] and severe acute stress dur-
ing adult life may promote migraine as well, given the
evidence that post-traumatic-stress disorder seems to be
increased in migraine patients [21]. Interestingly, early
life stress is a risk factor for developing depression [22], a
disorder with increased comorbidity with migraine (see
below), and first evidence has also associated it with
alterations of the immune system [23,24], a condition
that is also associated with migraine (see below). It is
therefore conceivable that stress may produce long-last-
ing changes in the threshold for migraine attacks by
inducing epigenetic modifications throughout the brain.
Epigenetics in comorbidities of migraine
Depression and epilepsy are two disorders that display
bidirectional comorbidity with migraine. Moreover,
migraine is associated with an increased risk of cardiovas-
cular disease including stroke and myocardial infarction
[25]. Interestingly, depression also shares modulatory fac-
tors with migraine, such as female hormones and chronic
stress, the latter of which is an established risk factor for
depression [26]. A role for epigenetics has been suggested
for all these comorbid disorders of migraine, and has
already been extensively reviewed [27-29]. In summary,
the main proof for a role of epigenetic mechanisms in
depression is evident from animal models for major
depressive disorder that show large changes in epigenetic
programming of stress related genes (for example, Bdnf)
that could be reversed by antidepressant treatment
[30,31]. Moreover, a recent study reported differential
expression of DNMTs in peripheral white blood cells of
patients with major depressive disorder and bipolar disor-
der, suggesting that aberrant epigenetic gene regulation
may be associated with the pathophysiology of mood dis-
orders [32]. The contribution of epigenetics in epilepsy is
illustrated by the high occurrence of this disorder in Rett
syndrome and alpha thalassemia mental retardation, two
disorders caused by mutations in the epigenetic effector
proteins methyl CpG binding protein 2 (MeCP2) and
ATRX, respectively [33,34]. In addition, in the brain of
temporal lobe epilepsy patients increased DNA methyla-
tion was found at the promoter of Reelin [35], a gene
involved in brain plasticity whose reduced expression con-
tributes to epilepsy pathogenesis [36]. Also in blood and
tissue of cardiovascular disease patients, as well as in car-
diovascular disease models, aberrant DNA methylation
levels were found, both globally and at cardiovascular
disease associated genes [27]. Therefore, causal pathways
shared between migraine and its comorbid disorders may
be modulated by epigenetic mechanisms.
Epigenetics and chronification of migraine
Attack frequency may change over the lifetime of a
migraine patient and in some patients develops into
chronic migraine with attacks more than 15 days per
month [2]. As migraine patients with a high baseline
attack frequency have an increased risk for developing
chronic migraine [37], migraine attacks themselves might
promote the development of chronic migraine. Addition-
ally, recent studies have shown that synchronous neuronal
activity, such as occurs during CSD, results in changes in
epigenetic marks at genes involved in neuronal plasticity
and neuroprotection [38-40]. This fits with evidence that
epigenetic mechanisms are involved in the regulation of
basal synaptic activity (that is, long-term changes in synap-
tic activity levels) [41]. It is, therefore, conceivable that
increased neuronal activity in migraine alters the brain
epigenome, thereby promoting the subsequent migraine
attacks and creating a feed-forward loop (Figure 1) in
which epigenetic programming of genes and pathways
underlying excitability are altered towards a more sensitive
baseline.
Inflammation, migraine and epigenetics
Inflammation has long been suggested to play a role in
migraine. Firstly, proinflammatory cytokines are released
during CSD in rat hippocampus [42]. Interestingly, inflam-
matory mediators can induce gene expression changes by
altering epigenetic marks [43], while their expression can
be inhibited by HDAC inhibitor treatment [44]. Secondly,
immune mediators are involved in sensitization of nerve
endings in the meninges that promote the feeling of pain
[45]. This sensitization effect is the result of vasodilation
and the release of proinflammatory cytokines. Prolonged
inflammatory pain was shown to promote pain sensitivity
by causing histone hypoacetylation at the Gad2 gene,
which is involved in GABAergic signaling [46]. Therefore,
migraine-related pain may cause sensitization of certain
pain pathways via inflammation-induced changes in epige-
netic gene regulation.
Epigenetic risk factors for migraine
Many candidate gene association studies and recently also
genome-wide association studies (GWAS) have searched
for genetic factors underlying migraine heritability. Some
genetic factors increasing migraine susceptibility have
direct links to epigenetic mechanisms. For instance, DNA
polymorphisms in MTHFR (the gene for 5’,10’-methylene-
tetrahydrofolate reductase), a gene required for DNA
methylation, show a slight association with migraine in
some studies [47]. More recently, GWAS have identified
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several single nucleotide polymorphisms linked to
migraine pathophysiology [48-50] in genes or in regulatory
regions of genes involved in epigenetic processes, includ-
ing MTDH, MEF2D and PRDM16. For example, metad-
herin (MTDH) associates with nuclear factor B (NFB)
and a HAT to promote the expression of NFB target
genes [51]. Myocyte enhancer factor 2D (MEF2D) can tar-
get methyltransferase complexes to specific genes to mark
them for gene expression [52]. MEF2 has recently been
shown to be regulated via the glucocorticoid receptor [53],
which may be one of the mechanisms by which stress
hormones affect the epigenome. Finally, PR domain con-
taining 16 (PRDM16) is involved in positioning and
removing specific chromatin modifications at enhancer
regions of Notch target genes during olfactory neuron dif-
ferentiation in drosophila [54]. These studies suggest that
some of the migraine GWAS hits may contribute to devel-
oping migraine through epigenetic modifications at their
target genes. Despite great efforts, GWAS have until now
only explained a fraction of the total heritability of
migraine. One explanation for this so-called ‘missing herit-
ability’ is the fact that GWA approaches are unsuited for
capturing disease susceptibility DNA variants with a low
allele frequency, but which are expected to have a larger
effect size [55]; next generation sequencing is currently
used to identify such variants. Another possible explana-
tion could be that DNA is not the only carrier of heritable
information; epigenetic information can also be transmitted
across cell divisions and possibly even transgenerationally.
Recent techniques that couple array-based analysis or next
generation sequencing to methods to study epigenetic
marks enable genome-wide and high-throughput analysis
of epigenetic marks. These techniques can analyze histone
modifications (that is, by chromatin immunoprecipitation
(ChIP)) as well as DNA methylation (that is, by bisulfite
conversion of unmethylated cytosines or by immunopreci-
pitation of methylated DNA using antibodies (MeDIP) or
methyl binding domains (MBD)) [56]. It therefore seems
likely that the recently proposed epigenome-wide associa-
tion studies, that can associate epigenetic marks to a trait
(in addition to genetic variations found by GWAS) [57],
will soon be put to use to further discover factors involved
in migraine heritability. Because brain tissue from migraine
patients is scarcely available, it may be feasible to use DNA
banks consisting of large collections of stored DNA sam-
ples of migraine sufferers as a resource for identification of
heritable DNA methylation marks that predispose to
migraine.
Potential for migraine drugs with epigenetic action
As epigenetic regulation of gene expression is a dynamic
and reversible process, it is a perfect target for drugs.
Interestingly, one of the current prophylactic drugs for
migraine (valproate) is a HDAC inhibitor that facilitates
chromatin remodeling. Valproate is an anticonvulsive drug
with many modes of action and side effects [58]; therefore,
it is not certain that its beneficial effects result from its
effects on the epigenome. Interestingly, valproate is also
successfully used in the treatment of bipolar depression
[59]. Furthermore, in animal models for depression,
reduced HDAC activity is required for the restoration of
the effects of chronic stress on the epigenome by antide-
pressant treatment [30].
While several epigenetic drugs are in clinical trials for
the treatment of cancer, to date (with the exception of
valproate) there are currently no epigenetic drugs that
have gone into clinical trials for the treatment of neurop-
sychiatric disorders or migraine [60]. Developing drugs
that specifically target epigenetic mechanisms in the
brain will open up exciting new avenues for the prophy-
lactic treatment of migraine.
Conclusions
Migraine is a common and disabling brain disease. Today
its etiology is only partially known. In a subgroup of
patients the migraine attack frequencies may dramatically
increase up to near daily attacks, affecting their daily life,
but the exact mechanism for chronification is unknown.
Epigenetic mechanisms may underlie a part of migraine
pathophysiology (and even the chronification of migraine)
and therefore might provide a novel promising avenue for
improving pharmacotherapy. More research is required to
identify (epigenetic) targets that affect migraine pathophy-
siology as well as epigenetic drugs that specifically act to
modulate chromatin structure at migraine pathways and
can be used as a target in the prophylactic treatment for
migraine.
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